Document is current

Any future updates will be listed below

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Crossref DOI link: https://doi.org/10.1038/s41392-025-02229-4

Published Online: 2025-05-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark